Literature DB >> 18191334

Risk factors for pericardial effusion in inoperable esophageal cancer patients treated with definitive chemoradiation therapy.

Xiong Wei1, H Helen Liu, Susan L Tucker, Shulian Wang, Radhe Mohan, James D Cox, Ritsuko Komaki, Zhongxing Liao.   

Abstract

PURPOSE: To identify clinical and dosimetric factors influencing the risk of pericardial effusion (PCE) in patients with inoperable esophageal cancer treated with definitive concurrent chemotherapy and radiation therapy (RT). METHODS AND MATERIALS: Data for 101 patients with inoperable esophageal cancer treated with concurrent chemotherapy and RT from 2000 to 2003 at our institution were analyzed. The PCE was confirmed from follow-up chest computed tomography scans and radiologic reports, with freedom from PCE computed from the end of RT. Log-rank tests were used to identify clinical and dosimetric factors influencing freedom from PCE. Dosimetric factors were calculated from the dose-volume histogram for the whole heart and pericardium.
RESULTS: The crude rate of PCE was 27.7% (28 of 101). Median time to onset of PCE was 5.3 months (range, 1.0-16.7 months) after RT. None of the clinical factors investigated was found to significantly influence the risk of PCE. In univariate analysis, a wide range of dose-volume histogram parameters of the pericardium and heart were associated with risk of PCE, including mean dose to the pericardium, volume of pericardium receiving a dose greater than 3 Gy (V3) to greater than 50 Gy (V50), and heart volume treated to greater than 32-38 Gy. Multivariate analysis selected V30 as the only parameter significantly associated with risk of PCE.
CONCLUSIONS: High-dose radiation to the pericardium may strongly increase the risk of PCE. Such a risk may be reduced by minimizing the dose-volume of the irradiated pericardium and heart.

Entities:  

Mesh:

Year:  2008        PMID: 18191334     DOI: 10.1016/j.ijrobp.2007.10.056

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  65 in total

1.  Symptomatic cardiac toxicity is predicted by dosimetric and patient factors rather than changes in 18F-FDG PET determination of myocardial activity after chemoradiotherapy for esophageal cancer.

Authors:  Andre Konski; Tianyu Li; Michael Christensen; Jonathan D Cheng; Jian Q Yu; Kevin Crawford; Oleh Haluszka; Jeffrey Tokar; Walter Scott; Neal J Meropol; Steven J Cohen; Alan Maurer; Gary M Freedman
Journal:  Radiother Oncol       Date:  2012-06-07       Impact factor: 6.280

Review 2.  Technological advances in radiotherapy for esophageal cancer.

Authors:  Milan Vosmik; Jiri Petera; Igor Sirak; Miroslav Hodek; Petr Paluska; Jiri Dolezal; Marcela Kopacova
Journal:  World J Gastroenterol       Date:  2010-11-28       Impact factor: 5.742

Review 3.  Cardiac toxicity of lung cancer radiotherapy.

Authors:  Radovan Vojtíšek
Journal:  Rep Pract Oncol Radiother       Date:  2019-11-14

Review 4.  Cardiac side effects of conventional and particle radiotherapy in cancer patients.

Authors:  A Wittig; R Engenhart-Cabillic
Journal:  Herz       Date:  2011-06       Impact factor: 1.443

5.  Treatment with Corticosteroid for Pericardial Effusion in a Patient with Advanced Synchronous Esophageal and Gastric Cancers following Chemoradiotherapy.

Authors:  Satoshi Osawa; Takanori Yamada; Takeji Saitoh; Takashi Kosugi; Tomohiro Terai; Yasuhiro Takayanagi; Yasushi Hamaya; Ken Sugimoto; Mutsuhiro Ikuma
Journal:  Case Rep Gastroenterol       Date:  2010-07-24

6.  Predictive factors for pericardial effusion identified by heart dose-volume histogram analysis in oesophageal cancer patients treated with chemoradiotherapy.

Authors:  K Hayashi; Y Fujiwara; M Nomura; M Kamata; H Kojima; M Kohzai; K Sumita; N Tanigawa
Journal:  Br J Radiol       Date:  2014-11-27       Impact factor: 3.039

7.  Dosimetric predictors of radiation-induced pericardial effusion in esophageal cancer.

Authors:  Ichiro Ogino; Shigenobu Watanabe; Kentaro Sakamaki; Yuka Ogino; Chikara Kunisaki; Kazuo Kimura
Journal:  Strahlenther Onkol       Date:  2017-04-19       Impact factor: 3.621

8.  Bayesian regression analyses of radiation modality effects on pericardial and pleural effusion and survival in esophageal cancer.

Authors:  Liru He; Andrew Chapple; Zhongxing Liao; Ritsuko Komaki; Peter F Thall; Steven H Lin
Journal:  Radiother Oncol       Date:  2016-08-22       Impact factor: 6.280

9.  Volumetric modulated arc therapy (VMAT) in the treatment of esophageal cancer patients.

Authors:  Stefania Martini; Francesca Arcadipane; Paolo Strignano; Rosella Spadi; Viviana Contu; Christian Fiandra; Riccardo Ragona; Giorgia Catalano; Maria Antonietta Satolli; Michele Camandona; Renato Romagnoli; Umberto Ricardi; Pierfrancesco Franco
Journal:  Med Oncol       Date:  2018-10-04       Impact factor: 3.064

10.  Stereotactic body radiotherapy for cardiac and paracardiac metastases: University of Florence experience.

Authors:  Pierluigi Bonomo; Lorenzo Livi; Andrea Rampini; Icro Meattini; Benedetta Agresti; Gabriele Simontacchi; Fabiola Paiar; Monica Mangoni; Ivano Bonucci; Daniela Greto; Laura Masi; Raffaella Doro; Livia Marrazzo; Giampaolo Biti
Journal:  Radiol Med       Date:  2013-05-28       Impact factor: 3.469

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.